Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China. (15th March 2022)
- Record Type:
- Journal Article
- Title:
- Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China. (15th March 2022)
- Main Title:
- Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China
- Authors:
- Liu, Min
He, Xiao‐Qing
Deng, Ren‐Ni
Tang, Sheng‐Quan
Harypursat, Vijay
Lu, Yan‐Qiu
He, Kun
Huo, Qin
Yang, Hong‐Hong
Liu, Qian
Chen, Yao‐Kai - Other Names:
- Wang Fu‐Sheng guestEditor.
- Abstract:
- Abstract: Objectives: The emergence of pretreatment drug resistance (PDR) caused by increased usage of antiretroviral therapy (ART) represents a significant challenge to HIV management. In this study, we evaluated the prevalence of PDR in people living with HIV (PLWH) in Chongqing, China. Methods: We retrospectively collected the data of 1110 ART‐naïve PLWH in Chongqing from January 1, 2018 to June 30, 2021. HIV‐1 genotypes and drug resistance were analyzed using the HIV‐1 pol sequence. Risk factors associated with PDR were evaluated via the logistic regression model. Results: Nine genotypes were detected among 1110 participants, with CRF07_BC (55.68%) being the dominant genotype, followed by CRF01_AE (21.44%), CRF08_BC (14.14%), and other genotypes (8.74%). Of all the participants, 24.14% exhibited drug resistance mutations (DRMs). The predominant DRMs for non‐nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs). The total prevalence of PDR was 10.54%, with 2.43%, 7.66%, and 1.71% participants exhibiting PDR to NRTIs, NNRTIs, and PIs, respectively. Furthermore, female PLWH, delays in ART initiation, and the CRF08_BC genotype were associated with a higher risk of PDR. Conclusions: Our study provides the first large cohort data on the prevalence of PDR in Chongqing,Abstract: Objectives: The emergence of pretreatment drug resistance (PDR) caused by increased usage of antiretroviral therapy (ART) represents a significant challenge to HIV management. In this study, we evaluated the prevalence of PDR in people living with HIV (PLWH) in Chongqing, China. Methods: We retrospectively collected the data of 1110 ART‐naïve PLWH in Chongqing from January 1, 2018 to June 30, 2021. HIV‐1 genotypes and drug resistance were analyzed using the HIV‐1 pol sequence. Risk factors associated with PDR were evaluated via the logistic regression model. Results: Nine genotypes were detected among 1110 participants, with CRF07_BC (55.68%) being the dominant genotype, followed by CRF01_AE (21.44%), CRF08_BC (14.14%), and other genotypes (8.74%). Of all the participants, 24.14% exhibited drug resistance mutations (DRMs). The predominant DRMs for non‐nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs). The total prevalence of PDR was 10.54%, with 2.43%, 7.66%, and 1.71% participants exhibiting PDR to NRTIs, NNRTIs, and PIs, respectively. Furthermore, female PLWH, delays in ART initiation, and the CRF08_BC genotype were associated with a higher risk of PDR. Conclusions: Our study provides the first large cohort data on the prevalence of PDR in Chongqing, China. HIV‐1 genotypes are diverse and complex, with a moderate level of PDR, which does not reach the threshold for the initiation of a public health response. Nevertheless, continuous surveillance of PDR is both useful and advisable. … (more)
- Is Part Of:
- HIV medicine. Volume 23(2022)supplement 1
- Journal:
- HIV medicine
- Issue:
- Volume 23(2022)supplement 1
- Issue Display:
- Volume 23, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 23
- Issue:
- 1
- Issue Sort Value:
- 2022-0023-0001-0000
- Page Start:
- 95
- Page End:
- 105
- Publication Date:
- 2022-03-15
- Subjects:
- genotype -- HIV‐1 -- mutation -- pretreatment drug resistance -- risk factors
HIV infections -- Treatment -- Periodicals
HIV-positive persons -- Periodicals
HIV infections -- Treatment -- Decision making -- Periodicals
616.9792 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=hiv ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1468-1293 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/hiv.13253 ↗
- Languages:
- English
- ISSNs:
- 1464-2662
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4319.045900
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21659.xml